Josh Bilenker and his Loxo crew are tak­ing the reins on on­col­o­gy R&D at Eli Lil­ly, culling the weak and map­ping a new path

Josh Bilenker, Jake Van Naar­den and Nisha Nan­da came out of Eli Lil­ly’s $8 bil­lion Loxo On­col­o­gy buy­out with a bun­dle of cash and plen­ty of choic­es on what they could do next. Start a new com­pa­ny, go pub­lic. Live on the beach in 5-star lux­u­ry. Con­tem­plate the stars — in their own ob­ser­va­to­ry.

So what are they do­ing?

They formed a new ex­ec­u­tive team that is tak­ing over the man­age­ment of Eli Lil­ly’s hun­dreds-strong on­col­o­gy R&D group — es­sen­tial­ly us­ing Loxo as a base for a bold new ex­per­i­ment in Big Phar­ma R&D in an at­tempt to cre­ate a true biotech en­vi­ron­ment with the deep pock­ets of a top-15 in­dus­try play­er. They’ve re­cruit­ed David Hy­man from Memo­r­i­al Sloan Ket­ter­ing to join the team as chief med­ical of­fi­cer. And the man­date in­cludes culling out the on­col­o­gy pipeline, high­light­ing their star prospects and go­ing af­ter new pro­grams wher­ev­er they can find the best prospects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER